Investors Are Paying Attention to This Pharma That Is Gaining Speed
Pharmaceutical companies develop treatments for patients with serious diseases, and when one of these companies has a drug candidate nearing application for review (and, hopefully, approval), the excitement with each piece of news can drive investors toward the company's stock.
Harmony Biosciences Holdings (NASDAQ: HRMY) is one such drugmaker that has experienced its own share price growth. The company's success has hinged on its sole product, Wakix, which has been approved by the Food and Drug Administration (FDA) for treating people who suffer from excessive daytime sleepiness and cataplexy (muscle weakness) as a result of narcolepsy.
Now the company is looking to expand its portfolio, treating long-term investors with a potential boost to their portfolios.
Source Fool.com
